- Why Research
- Our Impact
- Get Involved
- About BCRF
- Contact Us
- Cancer Divides. We Unite.
You are here
Powel H. Brown, MD, PhD
John Charles Cain Distinguished Chair
Department of Clinical Cancer Prevention
University of Texas MD Anderson Cancer Center
Seeking to identify new targets for the treatment and prevention of breast cancer.
Newly targeted therapies are tested in laboratory models of triple negative breast cancer (TNBC).
While still early in development,these studies will enable development of novel therapeutic strategies to treat TNBCs.
Dr. Brown and his team are investigating whether drugs that block specific cell signaling pathways are useful for the treatment and prevention of breast cancer. They are particularly interested in identifying new drug targets for the treatment of triple negative breast cancer (TNBC) and other estrogen receptor (ER)-negative breast cancers.
In previous analyses of gene expression in TNBC, his team identified 23 highly expressed transcription factors (molecules that turn genes on or off), including six that belong to the SOX family of transcription factors. Early experiments suggest that SOX9 is essential for breast cancer cell growth, migration, and invasion. High SOX9 expression in breast cancer is associated with poor prognosis, and SOX9 regulates the expression of molecules that control cell invasion.
This year, they will test the effect of targeting SOX9, alone and in combintation with other agents, on tumor growth, survival and metastasis in laboratory models of TNBC. These studies will enable development of novel therapeutic strategies to treat TNBCs.
Powel Brown is a medical oncologist and physician-scientist specializing in breast cancer treatment and prevention at the University of Texas, MD Anderson Cancer Center, where he is Chair of the Department of Clinical Cancer Prevention. He is conducting studies to identify novel targets for the treatment and prevention of breast cancer, particularly estrogen receptor (ER)-negative breast cancer. His team has conducted a BCRF-funded clinical trial of the kinase inhibitor lapatinib for the treatment of women with DCIS breast cancer. The results from this study will demonstrate whether lapatinib suppresses the growth of DCIS cells, and will be used to plan future DCIS breast cancer clinical trials to prevent the development of invasive breast cancer. Dr. Brown is also conducting preclinical studies of the signaling molecules in breast cancer with a particular focus on identifying the molecular drivers of "triple-negative" breast cancers. His research group has successfully identified several signaling pathways critical for breast cancer growth and development. Dr. Brown is also studying the death-associated protein kinase DAPK1, which his team has identified as one of the most highly expressed kinases in ER-negative breast cancer. This research will determine whether DAPK1 inhibitors suppress growth of p53-mutant breast cancer cells, the resistance pathways associated with DAPK1 inhibitors, and the ability of DAPK1 inhibitors to enhance the preventive effects of standard chemotherapeutic strategies. These studies will provide the foundation to target DAPK for the treatment of triple-negative breast cancers, the most aggressive form of breast cancer.
BCRF Investigator Since